Synergetic Regulation of Cancer Cells and Exhausted T Cells to Fight Cold Tumors with a Fluorinated EGCG-based Nanocomplex

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Nov 14

PMID 37957632

Authors

Jinlin Zhang

Mingyue Wang

Doudou He

Liang Zhang

Tianqing Liu

Kaikai Wang

Affiliations

Soon will be listed here.

Abstract

Immune therapy that targets PD-L1 (programmed cell death-ligand 1) is attractive to augment immune response by breaking the programmed cell death-1 (PD-1)/PD-L1 axis. However, T cell exhaustion associated with insufficient T cells infiltration may diminish the efficacy of cancer therapy. Here, we report a novel delivery system of FEGCG/FPEI@siTOX composed of fluorinated EGCG (FEGCG) and fluorinated polyethyleneimine (FPEI) for delivery of small interfering RNA anti-TOX (thymus high mobility group box protein, TOX) to treat tumor and metastasis. In this way, the reduction in PD-L1 expression by FEGCG can promote T-cell function, while inhibition of TOX expression with siTOX can alleviate T-cell exhaustion. FPEI are designed to deliver siRNA with high efficiency and low toxicity compared to classical PEI. Integrating FEGCG, FPEI and siTOX into such a novel system resulted in excellent anti-tumor and antimetastatic effects. It is a promising delivery system and potential strategy for the treatment of "cold" tumors.

Citing Articles

Steady-State Delivery and Chemical Modification of Food Nutrients to Improve Cancer Intervention Ability.

Hao S, Ge P, Su W, Wang Y, Abd El-Aty A, Tan M Foods. 2024; 13(9).

PMID: 38731734 PMC: 11083276. DOI: 10.3390/foods13091363.

References

Gao Z, Jia S, Ou H, Hong Y, Shan K, Kong X . An Activatable Near-Infrared Afterglow Theranostic Prodrug with Self-Sustainable Magnification Effect of Immunogenic Cell Death. Angew Chem Int Ed Engl. 2022; 61(40):e202209793. DOI: 10.1002/anie.202209793. View

Zhao Z, Chen C, Wu W, Wang F, Du L, Zhang X . Highly efficient photothermal nanoagent achieved by harvesting energy via excited-state intramolecular motion within nanoparticles. Nat Commun. 2019; 10(1):768. PMC: 6377612. DOI: 10.1038/s41467-019-08722-z. View

Morris E, Neelapu S, Giavridis T, Sadelain M . Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2021; 22(2):85-96. PMC: 8127450. DOI: 10.1038/s41577-021-00547-6. View

Wu P, Luo X, Wu H, Zhang Q, Dai Y, Sun M . Efficient and targeted chemo-gene delivery with self-assembled fluoro-nanoparticles for liver fibrosis therapy and recurrence. Biomaterials. 2020; 261:120311. DOI: 10.1016/j.biomaterials.2020.120311. View

Lv J, Cheng Y . Fluoropolymers in biomedical applications: state-of-the-art and future perspectives. Chem Soc Rev. 2021; 50(9):5435-5467. DOI: 10.1039/d0cs00258e. View

Wu P, Zhang H, Yin Y, Sun M, Mao S, Chen H . Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. Adv Sci (Weinh). 2022; 9(15):e2105894. PMC: 9131592. DOI: 10.1002/advs.202105894. View

Xu J, Lv J, Zhuang Q, Yang Z, Cao Z, Xu L . A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020; 15(12):1043-1052. DOI: 10.1038/s41565-020-00781-4. View

Wu Y, Ju Q, Jia K, Yu J, Shi H, Wu H . Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Int J Cancer. 2018; 143(1):45-51. DOI: 10.1002/ijc.31301. View

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

10.

Huang X, Wu G, Liu C, Hua X, Tang Z, Xiao Y . Intercalation-Driven Formation of siRNA Nanogels for Cancer Therapy. Nano Lett. 2021; 21(22):9706-9714. DOI: 10.1021/acs.nanolett.1c03539. View

11.

Chen S, Zhu S, Pei X, Qiu B, Xiong D, Long X . Cancer cell-derived exosomal circUSP7 induces CD8 T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC. Mol Cancer. 2021; 20(1):144. PMC: 8576933. DOI: 10.1186/s12943-021-01448-x. View

12.

Arcia-Anaya D, Elliott T . STAT5A antagonizes TOX in CD8 T cell exhaustion. Nat Rev Immunol. 2023; 23(2):73. DOI: 10.1038/s41577-022-00833-x. View

13.

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

14.

Chen C, Ni X, Jia S, Liang Y, Wu X, Kong D . Massively Evoking Immunogenic Cell Death by Focused Mitochondrial Oxidative Stress using an AIE Luminogen with a Twisted Molecular Structure. Adv Mater. 2019; 31(52):e1904914. DOI: 10.1002/adma.201904914. View

15.

Shao H, Cheng S, Yao M, Ji X, Zhong H, Wang D . A pH-response chemotherapy synergistic photothermal therapy for tumor suppression and bone regeneration by mussel-inspired Mg implant. Regen Biomater. 2021; 8(6):rbab053. PMC: 8455343. DOI: 10.1093/rb/rbab053. View

16.

Wu P, Zhang H, Sun M, Mao S, He Q, Shi Y . Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier-Free Nanoassembly of Fluorinated Prodrug and siRNA. Adv Mater. 2022; 34(38):e2203019. DOI: 10.1002/adma.202203019. View

17.

Li Z, Wang Y, Shen Y, Qian C, Oupicky D, Sun M . Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti-PD-L1 immunotherapy. Sci Adv. 2020; 6(20):eaaz9240. PMC: 7228744. DOI: 10.1126/sciadv.aaz9240. View

18.

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

19.

Ni X, Zhang X, Duan X, Zheng H, Xue X, Ding D . Near-Infrared Afterglow Luminescent Aggregation-Induced Emission Dots with Ultrahigh Tumor-to-Liver Signal Ratio for Promoted Image-Guided Cancer Surgery. Nano Lett. 2018; 19(1):318-330. DOI: 10.1021/acs.nanolett.8b03936. View

20.

Han H, Jeong S, Kim H, Kim H, Kim A, Kwon M . TOX-expressing terminally exhausted tumor-infiltrating CD8 T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 2020; 499:137-147. DOI: 10.1016/j.canlet.2020.11.035. View